![]() Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. 16 hours ago &0183 &32 On the low end, Axsomes management believes the companys first two commercial-stage products should deliver at least 1.3 billion in peak sales. With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding JAZZ to their portfolios. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. JAZZ has an average earnings surprise of 10.9%. The Zacks Consensus Estimate has increased $0.29 to $17.35 per share. 10 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2022. Revenues for the chipmaker also exceeded expectations, coming in at 7.19 billion. Value investors don't just pay attention to a company's valuation ratios positive earnings play a crucial role, too. The company reported an adjusted EPS of 1.09 while the market had expected 0.92, making this a beat of 0.17. Value investors should also note JAZZ's Price/Sales ratio of 2.7X. Additionally, JAZZ has a PEG Ratio of 1.1 and a Price/Cash Flow ratio of 6.6X. Shares are currently trading at a forward P/E of 8.7X for the current fiscal year compared to the Medical - Drugs industry's P/E of 15.4X. JAZZ is a Zacks Rank #3 (Hold) stock, with a Value Style Score of B and VGM Score of B. This compares to earnings of 4.21 per share a year ago. Xywav was also approved for treating idiopathic hypersomnia (IH). Jazz Pharmaceuticals (JAZZ) came out with a quarterly loss of 0.07 per share versus the Zacks Consensus Estimate of 0.51. Both drugs are approved for treating cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients. And Wall Street continues to be enamored with the drugmaker, which has a consensus buy rating, according to Yahoo Finance. Xywav is a low-sodium formulation of Jazz’s legacy drug, Xyrem, which was launched in 2020. Over the past year, the companys shares are up by 17. The company derives the majority of its revenues from its sleep disorder drugs - Xywav and Xyrem. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks.ĭublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience and oncology. Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data. It received approval for two new drugs' Zepzelca & Rylaze'.Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. Find the latest JAZZ231215C00130000 (JAZZ231215C00130000) stock quote. Jazz Pharmaceuticals plc (JAZZ) stock historical prices & data Yahoo Finance JAZZ - Jazz Pharmaceuticals plc NasdaqGS - NasdaqGS Real-time price. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. ![]() Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. Jazz Pharmaceuticals Historical Annual Stock Price Data
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |